Endocrine

, Volume 50, Issue 2, pp 355–367 | Cite as

Short-term administration of GW501516 improves inflammatory state in white adipose tissue and liver damage in high-fructose-fed mice through modulation of the renin-angiotensin system

  • D’Angelo C. Magliano
  • Aline Penna-de-Carvalho
  • Manuel Vazquez-Carrera
  • Carlos A. Mandarim-de-Lacerda
  • Marcia B. Aguila
Original Article

Abstract

High activation of the angiotensin-converting enzyme (ACE)/(angiotensin-II type 1 receptor) AT1r axis is closely linked to pro-inflammatory effects and liver damage. The aim of this study was to evaluate the effects of the short-term administration of GW501516 on pro-inflammatory markers in white adipose tissue (WAT) and hepatic stellate cells (HSCs), lipogenesis and insulin resistance in the liver upon high-fructose diet (HFru)-induced ACE/AT1r axis activation. Three-month-old male C57Bl/6 mice were fed a standard chow diet or a HFru for 8 weeks. Then, the animals were separated randomly into four groups and treated with GW501516 for 3 weeks. Morphological variables, systolic blood pressure, and plasma determinations were analyzed. In the WAT, the ACE/AT1r axis and pro-inflammatory cytokines were assessed, and in the liver, the ACE/AT1r axis, HSCs, fatty acid oxidation, insulin resistance, and AMPK activation were evaluated. The HFru group displayed a high activation of the ACE/AT1r axis in both the WAT and liver; consequently, we detected inflammation and liver damage. Although GW501516 abolished the increased activation of the ACE/AT1r axis in the WAT, no differences were found in the liver. GW501516 blunted the inflammatory state in the WAT and reduced HSC activation in the liver. In addition, GW501516 alleviates damage in the liver by increasing the expression of the genes that regulate beta-oxidation and decreasing the expression of the genes and proteins that are involved in lipogenesis and gluconeogenesis. We conclude that GW501516 may serve as a therapeutic option for the treatment of a highly activated ACE/AT1r axis in WAT and liver.

Keywords

ACE/AT1r axis GW501516 Hepatic stellate cells AMPK Inflammation 

References

  1. 1.
    R. Weiss, F.R. Kaufman, Metabolic complications of childhood obesity: identifying and mitigating the risk. Diabetes Care 31(Suppl 2), S310–S316 (2008)CrossRefPubMedGoogle Scholar
  2. 2.
    N. Anderson, J. Borlak, Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis. Pharmacol. Rev. 60, 311–357 (2008)CrossRefPubMedGoogle Scholar
  3. 3.
    M. Laville, J.A. Nazare, Diabetes, insulin resistance and sugars. Obes. Rev. 10(Suppl 1), 24–33 (2009)CrossRefPubMedGoogle Scholar
  4. 4.
    C. Couchepin, K.A. Le, M. Bortolotti, J.A. da Encarnacao, J.B. Oboni, C. Tran et al., Markedly blunted metabolic effects of fructose in healthy young female subjects compared with male subjects. Diabetes Care 31, 1254–1256 (2008)CrossRefPubMedGoogle Scholar
  5. 5.
    D.I. Jalal, G. Smits, R.J. Johnson, M. Chonchol, Increased fructose associates with elevated blood pressure. J. Am. Soc. Nephrol. 21, 1543–1549 (2010)PubMedCentralCrossRefPubMedGoogle Scholar
  6. 6.
    L. Tappy, K.A. Le, Metabolic effects of fructose and the worldwide increase in obesity. Physiol. Rev. 90, 23–46 (2010)CrossRefPubMedGoogle Scholar
  7. 7.
    S.H. Santos, L.R. Fernandes, C.S. Pereira, A.L. Guimaraes, A.M. de Paula, M.J. Campagnole-Santos et al., Increased circulating angiotensin-(1–7) protects white adipose tissue against development of a proinflammatory state stimulated by a high-fat diet. Regul. Pept. 178, 64–70 (2012)CrossRefPubMedGoogle Scholar
  8. 8.
    T. Fukui, T. Hirano, Y. Shiraishi, M. Nagashima, M. Adachi, Chronic insulin infusion normalizes blood pressure and the gene expressions of angiotensin II type 1 receptor in fructose-fed rats. Hypertens. Res. 31, 127–133 (2008)CrossRefPubMedGoogle Scholar
  9. 9.
    S.H. Santos, L.R. Fernandes, E.G. Mario, A.V. Ferreira, L.C. Porto, J.I. Alvarez-Leite et al., Mas deficiency in FVB/N mice produces marked changes in lipid and glycemic metabolism. Diabetes 57, 340–347 (2008)CrossRefPubMedGoogle Scholar
  10. 10.
    M. Granzow, R. Schierwagen, S. Klein, B. Kowallick, S. Huss, M. Linhart et al., Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis. Hepatology 60, 334–348 (2014)CrossRefPubMedGoogle Scholar
  11. 11.
    K. Uyeda, J.J. Repa, Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis. Cell Metab. 4, 107–110 (2006)CrossRefPubMedGoogle Scholar
  12. 12.
    N. Roglans, L. Vila, M. Farre, M. Alegret, R.M. Sanchez, M. Vazquez-Carrera et al., Impairment of hepatic Stat-3 activation and reduction of PPARalpha activity in fructose-fed rats. Hepatology 45, 778–788 (2007)CrossRefPubMedGoogle Scholar
  13. 13.
    L. Serrano-Marco, E. Barroso, I. El Kochairi, X. Palomer, L. Michalik, W. Wahli et al., The peroxisome proliferator-activated receptor (PPAR) beta/delta agonist GW501516 inhibits IL-6-induced signal transducer and activator of transcription 3 (STAT3) activation and insulin resistance in human liver cells. Diabetologia 55, 743–751 (2012)CrossRefPubMedGoogle Scholar
  14. 14.
    L. Serrano-Marco, R. Rodriguez-Calvo, I. El Kochairi, X. Palomer, L. Michalik, W. Wahli et al., Activation of peroxisome proliferator-activated receptor-beta/-delta (PPAR-beta/-delta) ameliorates insulin signaling and reduces SOCS3 levels by inhibiting STAT3 in interleukin-6-stimulated adipocytes. Diabetes 60, 1990–1999 (2011)PubMedCentralCrossRefPubMedGoogle Scholar
  15. 15.
    T. Coll, E. Barroso, D. Alvarez-Guardia, L. Serrano, L. Salvado, M. Merlos et al., The role of peroxisome proliferator-activated receptor beta/delta on the inflammatory basis of metabolic disease. PPAR Res. (2010). doi:10.1155/2010/368467 PubMedCentralPubMedGoogle Scholar
  16. 16.
    M.J. Zarzuelo, R. Jimenez, P. Galindo, M. Sanchez, A. Nieto, M. Romero et al., Antihypertensive effects of peroxisome proliferator-activated receptor-beta activation in spontaneously hypertensive rats. Hypertension 58, 733–743 (2011)CrossRefPubMedGoogle Scholar
  17. 17.
    D.K. Kramer, L. Al-Khalili, B. Guigas, Y. Leng, P.M. Garcia-Roves, A. Krook, Role of AMP kinase and PPARdelta in the regulation of lipid and glucose metabolism in human skeletal muscle. J. Biol. Chem. 282, 19313–19320 (2007)CrossRefPubMedGoogle Scholar
  18. 18.
    D.C. Magliano, T.C. Bargut, S.N. de Carvalho, M.B. Aguila, C.A. Mandarim-de-Lacerda, V. Souza-Mello, Peroxisome proliferator-activated receptors-alpha and gamma are targets to treat offspring from maternal diet-induced obesity in mice. PLoS One 8, 64258 (2013)CrossRefGoogle Scholar
  19. 19.
    M. Catta-Preta, L.S. Mendonca, J. Fraulob-Aquino, M.B. Aguila, C.A. Mandarim-de-Lacerda, A critical analysis of three quantitative methods of assessment of hepatic steatosis in liver biopsies. Virchows Arch. 459, 477–485 (2011)CrossRefPubMedGoogle Scholar
  20. 20.
    M.B. Aguila, A.R. Pinheiro, L.B. Parente, C.A. Mandarim-de-Lacerda, Dietary effect of different high-fat diet on rat liver stereology. Liver Int. 23, 363–370 (2003)CrossRefPubMedGoogle Scholar
  21. 21.
    S. Barbosa-da-Silva, N.C. da Silva, M.B. Aguila, C.A. Mandarim-de-Lacerda, Liver damage is not reversed during the lean period in diet-induced weight cycling in mice. Hepatol. Res. 44, 450–459 (2014)CrossRefPubMedGoogle Scholar
  22. 22.
    A. Spruss, G. Kanuri, S. Wagnerberger, S. Haub, S.C. Bischoff, I. Bergheim, Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice. Hepatology 50, 1094–1104 (2009)CrossRefPubMedGoogle Scholar
  23. 23.
    A. Schultz, D. Neil, M.B. Aguila, C.A. Mandarim-de-Lacerda, Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int. J. Mol. Sci. 14, 21873–21886 (2013)PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    N. Sharma, L. Li, C.M. Ecelbarger, Sex differences in renal and metabolic responses to a high-fructose diet in mice. Am. J. Physiol. Renal Physiol. 308, F400–F410 (2015)CrossRefPubMedGoogle Scholar
  25. 25.
    L.A. Bojic, D.E. Telford, M.D. Fullerton, R.J. Ford, B.G. Sutherland, J.Y. Edwards et al., PPARdelta activation attenuates hepatic steatosis in Ldlr−/− mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity. J. Lipid Res. 55, 1254–1266 (2014)PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    M.A. Prieto, A. Bettaieb, C.R. Lanzi, V.C. Soto, D.J. Perdicaro, C.R. Galmarini et al., Catechin and quercetin attenuate adipose inflammation in fructose-fed rats and in 3T3-L1 adipocytes. Mol. Nutr. Food Res. (2015). doi:10.1002/mnfr.201400631 Google Scholar
  27. 27.
    N. Mamikutty, Z.C. Thent, S.R. Sapri, N.N. Sahruddin, M.R. MohdYusof, F. Haji Suhaimi, The establishment of metabolic syndrome model by induction of fructose drinking water in male Wistar rats. BioMed Res. Int. 14, 263897 (2014)Google Scholar
  28. 28.
    W.X. Carroll, N.S. Kalupahana, S.L. Booker, N. Siriwardhana, M. Lemieux, A.M. Saxton et al., Angiotensinogen gene silencing reduces markers of lipid accumulation and inflammation in cultured adipocytes. Front. Endocrinol. 4, 10 (2013). doi:10.3389/fendo.2013.00010 CrossRefGoogle Scholar
  29. 29.
    E.S. Alves, A.A. Haidar, C.D. Quadros, D.S. Carvalho, D. Morgan, M.S. Rocha et al., Angiotensin II-induced JNK activation is mediated by NAD(P)H oxidase in isolated rat pancreatic islets. Regul. Pept. 175, 1–6 (2012)CrossRefPubMedGoogle Scholar
  30. 30.
    K. Nomura, T. Yamanouchi, The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J. Nutr. Biochem. 23, 203–208 (2012)CrossRefPubMedGoogle Scholar
  31. 31.
    Y. Nagai, Y. Nishio, T. Nakamura, H. Maegawa, R. Kikkawa, A. Kashiwagi, Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha. Am. J. Physiol. Endocrinol. Metab. 282, E1180–E1190 (2002)CrossRefPubMedGoogle Scholar
  32. 32.
    M.A. Lanaspa, L.G. Sanchez-Lozada, C. Cicerchi, N. Li, C.A. Roncal-Jimenez, T. Ishimoto et al., Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS One 7, e47948 (2012)PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    M.F. Abdelmalek, A. Suzuki, C. Guy, A. Unalp-Arida, R. Colvin, R.J. Johnson et al., Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 51, 1961–1971 (2010)PubMedCentralCrossRefPubMedGoogle Scholar
  34. 34.
    E. Barroso, A.M. Astudillo, J. Balsinde, M. Vazquez-Carrera, PPARbeta/delta Activation prevents hypertriglyceridemia caused by a high fat diet. Involvement of AMPK and PGC-1alpha-Lipin1-PPARalpha pathway. Clin. Investig. Arterioscler. 25, 63–73 (2013). doi:10.1016/j.arteri.2013.01.001 CrossRefPubMedGoogle Scholar
  35. 35.
    R.H. Houtkooper, E. Pirinen, J. Auwerx, Sirtuins as regulators of metabolism and health span. Nat. Rev. Mol. Cell Biol. 13, 225–238 (2012)CrossRefPubMedGoogle Scholar
  36. 36.
    C. Canto, J. Auwerx, PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 20, 98–105 (2009)PubMedCentralCrossRefPubMedGoogle Scholar
  37. 37.
    B. Viollet, L. Lantier, J. Devin-Leclerc, S. Hebrard, C. Amouyal, R. Mounier et al., Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front. Biosci. 14, 3380–3400 (2009)CrossRefGoogle Scholar
  38. 38.
    Y.G. Suh, W.I. Jeong, Hepatic stellate cells and innate immunity in alcoholic liver disease. World J. Gastroenterol. 17, 2543–2551 (2011)PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    M. Adachi, D.A. Brenner, High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase. Hepatology 47, 677–685 (2008)CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • D’Angelo C. Magliano
    • 1
    • 2
    • 3
  • Aline Penna-de-Carvalho
    • 1
  • Manuel Vazquez-Carrera
    • 2
    • 3
  • Carlos A. Mandarim-de-Lacerda
    • 1
  • Marcia B. Aguila
    • 1
  1. 1.Laboratory of Morphometry, Metabolism and Cardiovascular Disease, Biomedical Center, Institute of BiologyState University of Rio de JaneiroRio de JaneiroBrazil
  2. 2.Department of Pharmacology and Therapeutic Chemistry, Faculty of Pharmacy, Institute of Biomedicine of the University of Barcelona (IBUB)University of BarcelonaBarcelonaSpain
  3. 3.Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Diseases (CIBERDEM)-Instituto de Salud Carlos IIIMadridSpain

Personalised recommendations